Consistency in the safety labeling of bioequivalent medications

Jon Duke, Jeff Friedlin, Xiaochun Li

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: Bioequivalent medications are required by the Food and Drug Administration to have identical warnings on their labels. This requirement has both clinical and legal importance, yet has never been validated. We sought to determine the real-world consistency of electronic labeling for bioequivalent drugs from different manufacturers. Methods: Using natural language processing, we indexed the adverse drug reactions (ADRs) found in the Adverse Reactions and Post-Marketing sections of 9105 structured product labels. We calculated the standard deviation in ADR labeling for each bioequivalent drug and the percent deviation of each generic label from its corresponding brand. We also analyzed the performance of individual generic manufacturers. For the 25 drugs with the greatest discrepancy in labeled ADRs, we performed manual review to identify causes of inconsistency. Results: 68% of multi-manufacturer drugs had discrepancies in ADR labeling. For a given drug, the mean deviation in number of labeled ADRs was 4.4, and the median was 0.8 (IQR 0 to 3.2). The mean range in number of labeled ADRs was 12 +/- 0.9, and the median was 2 (IQR 0 to 9). Overall, 77.9% of generic manufacturers produced labels differing from brand. Causes of inconsistency included missing tables, outdated post-marketing reports, and formatting issues. Conclusions: Despite FDA mandate, bioequivalent drugs often differ in their safety labeling. Physicians should be aware of such differences and regulators should consider new strategies for harmonizing bioequivalent labels.

Original languageEnglish
Pages (from-to)294-301
Number of pages8
JournalPharmacoepidemiology and Drug Safety
Volume22
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Drug-Related Side Effects and Adverse Reactions
Drug Labeling
Safety
Pharmaceutical Preparations
Marketing
Natural Language Processing
United States Food and Drug Administration
Physicians

Keywords

  • Adverse reactions
  • Drug labeling
  • Drug safety
  • Generic medications
  • Pharmacoepidemiology

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Epidemiology

Cite this

Consistency in the safety labeling of bioequivalent medications. / Duke, Jon; Friedlin, Jeff; Li, Xiaochun.

In: Pharmacoepidemiology and Drug Safety, Vol. 22, No. 3, 03.2013, p. 294-301.

Research output: Contribution to journalArticle

@article{c6c83d9823d244bb9cb0475b6c80e3ce,
title = "Consistency in the safety labeling of bioequivalent medications",
abstract = "Purpose: Bioequivalent medications are required by the Food and Drug Administration to have identical warnings on their labels. This requirement has both clinical and legal importance, yet has never been validated. We sought to determine the real-world consistency of electronic labeling for bioequivalent drugs from different manufacturers. Methods: Using natural language processing, we indexed the adverse drug reactions (ADRs) found in the Adverse Reactions and Post-Marketing sections of 9105 structured product labels. We calculated the standard deviation in ADR labeling for each bioequivalent drug and the percent deviation of each generic label from its corresponding brand. We also analyzed the performance of individual generic manufacturers. For the 25 drugs with the greatest discrepancy in labeled ADRs, we performed manual review to identify causes of inconsistency. Results: 68{\%} of multi-manufacturer drugs had discrepancies in ADR labeling. For a given drug, the mean deviation in number of labeled ADRs was 4.4, and the median was 0.8 (IQR 0 to 3.2). The mean range in number of labeled ADRs was 12 +/- 0.9, and the median was 2 (IQR 0 to 9). Overall, 77.9{\%} of generic manufacturers produced labels differing from brand. Causes of inconsistency included missing tables, outdated post-marketing reports, and formatting issues. Conclusions: Despite FDA mandate, bioequivalent drugs often differ in their safety labeling. Physicians should be aware of such differences and regulators should consider new strategies for harmonizing bioequivalent labels.",
keywords = "Adverse reactions, Drug labeling, Drug safety, Generic medications, Pharmacoepidemiology",
author = "Jon Duke and Jeff Friedlin and Xiaochun Li",
year = "2013",
month = "3",
doi = "10.1002/pds.3351",
language = "English",
volume = "22",
pages = "294--301",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Consistency in the safety labeling of bioequivalent medications

AU - Duke, Jon

AU - Friedlin, Jeff

AU - Li, Xiaochun

PY - 2013/3

Y1 - 2013/3

N2 - Purpose: Bioequivalent medications are required by the Food and Drug Administration to have identical warnings on their labels. This requirement has both clinical and legal importance, yet has never been validated. We sought to determine the real-world consistency of electronic labeling for bioequivalent drugs from different manufacturers. Methods: Using natural language processing, we indexed the adverse drug reactions (ADRs) found in the Adverse Reactions and Post-Marketing sections of 9105 structured product labels. We calculated the standard deviation in ADR labeling for each bioequivalent drug and the percent deviation of each generic label from its corresponding brand. We also analyzed the performance of individual generic manufacturers. For the 25 drugs with the greatest discrepancy in labeled ADRs, we performed manual review to identify causes of inconsistency. Results: 68% of multi-manufacturer drugs had discrepancies in ADR labeling. For a given drug, the mean deviation in number of labeled ADRs was 4.4, and the median was 0.8 (IQR 0 to 3.2). The mean range in number of labeled ADRs was 12 +/- 0.9, and the median was 2 (IQR 0 to 9). Overall, 77.9% of generic manufacturers produced labels differing from brand. Causes of inconsistency included missing tables, outdated post-marketing reports, and formatting issues. Conclusions: Despite FDA mandate, bioequivalent drugs often differ in their safety labeling. Physicians should be aware of such differences and regulators should consider new strategies for harmonizing bioequivalent labels.

AB - Purpose: Bioequivalent medications are required by the Food and Drug Administration to have identical warnings on their labels. This requirement has both clinical and legal importance, yet has never been validated. We sought to determine the real-world consistency of electronic labeling for bioequivalent drugs from different manufacturers. Methods: Using natural language processing, we indexed the adverse drug reactions (ADRs) found in the Adverse Reactions and Post-Marketing sections of 9105 structured product labels. We calculated the standard deviation in ADR labeling for each bioequivalent drug and the percent deviation of each generic label from its corresponding brand. We also analyzed the performance of individual generic manufacturers. For the 25 drugs with the greatest discrepancy in labeled ADRs, we performed manual review to identify causes of inconsistency. Results: 68% of multi-manufacturer drugs had discrepancies in ADR labeling. For a given drug, the mean deviation in number of labeled ADRs was 4.4, and the median was 0.8 (IQR 0 to 3.2). The mean range in number of labeled ADRs was 12 +/- 0.9, and the median was 2 (IQR 0 to 9). Overall, 77.9% of generic manufacturers produced labels differing from brand. Causes of inconsistency included missing tables, outdated post-marketing reports, and formatting issues. Conclusions: Despite FDA mandate, bioequivalent drugs often differ in their safety labeling. Physicians should be aware of such differences and regulators should consider new strategies for harmonizing bioequivalent labels.

KW - Adverse reactions

KW - Drug labeling

KW - Drug safety

KW - Generic medications

KW - Pharmacoepidemiology

UR - http://www.scopus.com/inward/record.url?scp=84874511186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874511186&partnerID=8YFLogxK

U2 - 10.1002/pds.3351

DO - 10.1002/pds.3351

M3 - Article

C2 - 23042584

AN - SCOPUS:84874511186

VL - 22

SP - 294

EP - 301

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 3

ER -